Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2013 2
2014 2
2016 1
2017 2
2018 4
2019 1
2020 6
2021 6
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients.
Alexeyenko A, Brustugun OT, Eide IJZ, Gencheva R, Kosibaty Z, Lai Y, de Petris L, Tsakonas G, Grundberg O, Franzen B, Viktorsson K, Lewensohn R, Hydbring P, Ekman S. Alexeyenko A, et al. Among authors: tsakonas g. Transl Lung Cancer Res. 2022 Oct;11(10):2064-2078. doi: 10.21037/tlcr-22-236. Transl Lung Cancer Res. 2022. PMID: 36386450 Free PMC article.
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Kosibaty Z, Brustugun OT, Zwicky Eide IJ, Tsakonas G, Grundberg O, De Petris L, McGowan M, Hydbring P, Ekman S. Kosibaty Z, et al. Among authors: tsakonas g. Cancers (Basel). 2022 Jul 14;14(14):3430. doi: 10.3390/cancers14143430. Cancers (Basel). 2022. PMID: 35884490 Free PMC article.
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer.
Kaźmierczak D, Eide IJZ, Gencheva R, Lai Y, Lewensohn R, Tsakonas G, Grundberg O, de Petris L, McGowan M, Brustugun OT, Ekman S, Hydbring P. Kaźmierczak D, et al. Among authors: tsakonas g. Transl Lung Cancer Res. 2022 May;11(5):722-734. doi: 10.21037/tlcr-21-955. Transl Lung Cancer Res. 2022. PMID: 35693293 Free PMC article.
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Grønberg BH. Killingberg KT, et al. Among authors: tsakonas g. Lung Cancer. 2022 Apr;166:49-57. doi: 10.1016/j.lungcan.2022.02.002. Epub 2022 Feb 8. Lung Cancer. 2022. PMID: 35183991 Free article. Clinical Trial.
32 results